A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...
Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
Investor's Business Daily on MSN18h
AstraZeneca Stock Dives As China's Criminal Probe Rattles Its Third-Quarter BeatAstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, but AstraZeneca stock slipped amid a criminal probe in China.
ADCs, including the widely used cancer drug Enhertu (trastuzumab deruxtecan), represent a new wave of targeted therapies.
Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...
Some of the major updates include the approval of acalabrutinib (Calquence) for first-line treatment of mantle cell lymphoma, the FDA’s priority review of fam-trastuzumab deruxtecan-nxki (T-DXd; ...
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days ...
The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback